Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Rowe

Showing results (461-470 of 504) with videos related to

Pageof 51
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 29, 2026
PET-Based Outcome Prediction in Patients with Prostate Cancer Scheduled for [<sup>225</sup>Ac]Ac-PSMA Radiopharmaceutical TherapyLiam Widjaja, Sophie C Siegmund, Franz J Gildehaus, et al.
Clinical Nuclear Medicine|January 24, 2017
Defining the Added Value of 99mTc-MIBI SPECT/CT to Conventional Cross-Sectional Imaging in the Characterization of Enhancing Solid Renal MassesSara Sheikhbahaei, Christopher S Jones, Kristin K Porter, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 3, 2020
Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary TreatmentHossein Jadvar, Leslie K Ballas, Peter L Choyke, et al.
Medical Oncology (Northwood, London, England)|April 28, 2022
Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancerDiane K Reyes, Bruce J Trock, Phuoc T Tran, et al.
Diagnostics (Basel, Switzerland)|November 27, 2021
Whole-Body [<sup>18</sup>F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic DiseaseMatthias Fröhlich, Sebastian Serfling, Takahiro Higuchi, et al.
European Urology|March 19, 2023
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)Robert Seifert, Louise Emmett, Steven P Rowe, et al.
Oncotarget|July 21, 2016
[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinomaIl Minn, Soo Min Koo, Hye Soo Lee, et al.
The Journal of Urology|February 26, 2021
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with <sup>18</sup>F-DCFPyL in Prostate Cancer Patients (OSPREY)Kenneth J Pienta, Michael A Gorin, Steven P Rowe, et al.
Journal of Imaging Informatics in Medicine|April 8, 2024
An Automated Deep Learning-Based Framework for Uptake Segmentation and Classification on PSMA PET/CT Imaging of Patients with Prostate CancerYang Li, Maliha R Imami, Linmei Zhao, et al.
The Journal of Urology|April 15, 2021
Reply by AuthorsKenneth J Pienta, Michael A Gorin, Steven P Rowe, et al.
Pageof 51

Showing results (461-470 of 504) with videos related to

Sort By:
Pageof 51
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 29, 2026
PET-Based Outcome Prediction in Patients with Prostate Cancer Scheduled for [<sup>225</sup>Ac]Ac-PSMA Radiopharmaceutical TherapyLiam Widjaja, Sophie C Siegmund, Franz J Gildehaus, et al.
Clinical Nuclear Medicine|January 24, 2017
Defining the Added Value of 99mTc-MIBI SPECT/CT to Conventional Cross-Sectional Imaging in the Characterization of Enhancing Solid Renal MassesSara Sheikhbahaei, Christopher S Jones, Kristin K Porter, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 3, 2020
Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary TreatmentHossein Jadvar, Leslie K Ballas, Peter L Choyke, et al.
Medical Oncology (Northwood, London, England)|April 28, 2022
Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancerDiane K Reyes, Bruce J Trock, Phuoc T Tran, et al.
Diagnostics (Basel, Switzerland)|November 27, 2021
Whole-Body [<sup>18</sup>F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic DiseaseMatthias Fröhlich, Sebastian Serfling, Takahiro Higuchi, et al.
European Urology|March 19, 2023
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)Robert Seifert, Louise Emmett, Steven P Rowe, et al.
Oncotarget|July 21, 2016
[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinomaIl Minn, Soo Min Koo, Hye Soo Lee, et al.
The Journal of Urology|February 26, 2021
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with <sup>18</sup>F-DCFPyL in Prostate Cancer Patients (OSPREY)Kenneth J Pienta, Michael A Gorin, Steven P Rowe, et al.
Journal of Imaging Informatics in Medicine|April 8, 2024
An Automated Deep Learning-Based Framework for Uptake Segmentation and Classification on PSMA PET/CT Imaging of Patients with Prostate CancerYang Li, Maliha R Imami, Linmei Zhao, et al.
The Journal of Urology|April 15, 2021
Reply by AuthorsKenneth J Pienta, Michael A Gorin, Steven P Rowe, et al.
Pageof 51